AMY-101
AMY-101 (Cp40), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs) . AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation[1][2].
Product Specifications
CAS Number
1427001-89-5
Product Name Alternative
Cp40
UNSPSC
12352209
Target
Complement System; SARS-CoV
Type
Peptides
Related Pathways
Anti-infection; Immunology/Inflammation
Applications
COVID-19-anti-virus
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/amy-101.html
Purity
99.86
Solubility
H2O : 25 mg/mL (ultrasonic)
Smiles
CN1C2=CC=CC=C2C(C[C@H]3C(N[C@H](C(N[C@H](C(N[C@H](C(N(CC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CSSC[C@@H](C(N[C@H](C(N3)=O)C(C)C)=O)NC([C@H]([C@@H](C)CC)NC([C@H](N)CC4=CC=C(C=C4)O)=O)=O)C(N(C)[C@H](C(N)=O)[C@@H](C)CC)=O)=O)CCCNC(N)=N)=O)CC5=CN=CN5)=O)C)=O)C)=O)CC6=CNC7=CC=CC=C67)=O)CC(O)=O)=O)CCC(N)=O)=O)=C1
Molecular Formula
C83H117N23O18S2
Molecular Weight
1789.09
References & Citations
[1]Kajikawa T, et al. Safety and Efficacy of the Complement Inhibitor AMY-101 in a Natural Model of Periodontitis in Non-human Primates. Mol Ther Methods Clin Dev. 2017 Aug 18;6:207-215.|[2] Mastaglio S, et al. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020 Apr 29:108450|[3]Yanyan Liu, et al. Complement C3 Produced by Macrophages Promotes Renal Fibrosis via IL-17A Secretion. Front Immunol. 2018 Oct 22;9:2385.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
NBL1-13853 0.1 mg
NUDT10 Overexpression Lysate (Native) - (Dry Ice)
Sign In for Pricing
View Details 
